Fig. 3: Association of risk factors with survival.

Kaplan–Meier analyses of DFS (a) and OS (b) in patients with adverse molecular risk (n = 77) vs. intermediate/favorable molecular risk (n = 62). Patients with unknown molecular risk are also shown (n = 81). Kaplan–Meier analyses of DFS (c) and OS (d) in patients with ECOG 0–1 (n = 173) vs. 2–4 (n = 22). Kaplan–Meier analyses of DFS (e) and OS (f) in patients with Diagnosis-to-HCT interval of less than 6 months (n = 185) vs. at least 6 months (n = 35). OS overall survival, DFS disease-free survival, HCT hematopoietic cell transplantation, ECOG Eastern Cooperation Oncology Group score, IM intermediate, fav favorable, n.a. not assessed.